Incyte Corporation (INCY)
Dopo ore:
| Chiusura precedente | 84,97 |
| Aperto | 85,00 |
| Denaro | 75,01 x 800 |
| Lettera | 0,00 x 1000 |
| Min-Max giorno | 84,59 - 86,29 |
| Intervallo di 52 settimane | 65,07 - 86,29 |
| Volume | |
| Media Volume | 1.530.898 |
| Capitalizzazione | 19,135B |
| Beta (5 anni mensile) | 0,72 |
| Rapporto PE (ttm) | 21,50 |
| EPS (ttm) | 4,00 |
| Prossima data utili | 07 feb 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 87,13 |
- GlobeNewswire
Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil
MONTREAL, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for tafasitamab in combination with lenalidomide to ANVISA, the Brazilian health regulatory agency, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for auto
- GlobeNewswire
Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer
Elraglusib combination Phase 2 trial with retifanlimab based on observed synergy with immune checkpoint inhibitors, and preclinical and early clinical data supporting immunomodulatory activity of GSK-3β inhibitorsCHICAGO and FORT WORTH, Texas, March 01, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient on a Phase 2 study of elraglusib (9-ING-41) plus retifanlimab combined with gemcitabine/nab-paclitaxel fo
